Aclaris Therapeutics, Inc. (ACRS)
USD 3.08
(-5.52%)
USD 3.08
(-5.52%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -88.48 Million USD | 0.2% |
| 2022 | -88.66 Million USD | 22.42% |
| 2021 | -114.28 Million USD | -123.41% |
| 2020 | -51.15 Million USD | 64.19% |
| 2019 | -142.85 Million USD | -7.62% |
| 2018 | -132.73 Million USD | -93.71% |
| 2017 | -68.52 Million USD | -42.52% |
| 2016 | -48.07 Million USD | -133.81% |
| 2015 | -20.56 Million USD | -141.43% |
| 2014 | -8.51 Million USD | -62.66% |
| 2013 | -5.23 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -16.94 Million USD | -1036.22% |
| 2024 Q2 | -10.98 Million USD | 35.15% |
| 2023 Q4 | -1.49 Million USD | 94.9% |
| 2023 Q3 | -29.26 Million USD | 1.04% |
| 2023 Q2 | -29.56 Million USD | -12.0% |
| 2023 FY | -88.48 Million USD | 0.2% |
| 2023 Q1 | -26.4 Million USD | 20.69% |
| 2022 Q4 | -33.29 Million USD | -56.81% |
| 2022 Q2 | -16.67 Million USD | 4.58% |
| 2022 Q1 | -17.47 Million USD | 23.39% |
| 2022 FY | -88.66 Million USD | 22.42% |
| 2022 Q3 | -21.23 Million USD | -27.35% |
| 2021 FY | -114.28 Million USD | -123.41% |
| 2021 Q3 | -21.14 Million USD | -16.44% |
| 2021 Q4 | -22.8 Million USD | -7.84% |
| 2021 Q1 | -28.75 Million USD | -118.28% |
| 2021 Q2 | -18.16 Million USD | 36.84% |
| 2020 Q2 | -11.59 Million USD | 25.59% |
| 2020 FY | -51.15 Million USD | 64.19% |
| 2020 Q4 | -13.17 Million USD | -23.59% |
| 2020 Q1 | -15.58 Million USD | 16.18% |
| 2020 Q3 | -10.65 Million USD | 8.09% |
| 2019 Q2 | -49.87 Million USD | -32.77% |
| 2019 Q3 | -55.31 Million USD | -10.91% |
| 2019 FY | -142.85 Million USD | -7.62% |
| 2019 Q4 | -18.59 Million USD | 66.39% |
| 2019 Q1 | -37.56 Million USD | 2.56% |
| 2018 Q3 | -32.74 Million USD | -4.88% |
| 2018 FY | -132.73 Million USD | -93.71% |
| 2018 Q4 | -38.55 Million USD | -17.75% |
| 2018 Q2 | -31.21 Million USD | -3.27% |
| 2018 Q1 | -30.22 Million USD | -31.81% |
| 2017 Q2 | -14.83 Million USD | -18.15% |
| 2017 Q3 | -18.19 Million USD | -22.6% |
| 2017 Q4 | -22.93 Million USD | -26.07% |
| 2017 FY | -68.52 Million USD | -42.52% |
| 2017 Q1 | -12.55 Million USD | -9.45% |
| 2016 Q4 | -11.47 Million USD | -7.3% |
| 2016 Q3 | -10.69 Million USD | 16.91% |
| 2016 FY | -48.07 Million USD | -133.81% |
| 2016 Q1 | -13.03 Million USD | -176.6% |
| 2016 Q2 | -12.87 Million USD | 1.29% |
| 2015 Q3 | -10.63 Million USD | -309.91% |
| 2015 Q1 | -2.62 Million USD | -1.0% |
| 2015 Q4 | -4.71 Million USD | 55.67% |
| 2015 Q2 | -2.59 Million USD | 1.11% |
| 2015 FY | -20.56 Million USD | -141.43% |
| 2014 FY | -8.51 Million USD | -62.66% |
| 2014 Q3 | -2.65 Million USD | -27.22% |
| 2014 Q4 | -2.59 Million USD | 2.26% |
| 2014 Q2 | -2.08 Million USD | 0.0% |
| 2014 Q1 | -2.08 Million USD | 0.0% |
| 2013 FY | -5.23 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 61.943% |
| Prenetics Global Limited | -62.72 Million USD | -41.064% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -5615.827% |
| CareDx, Inc | -190.28 Million USD | 53.501% |
| Exact Sciences Corporation | -204.14 Million USD | 56.659% |
| Exagen Inc. | -23.68 Million USD | -273.511% |
| Inotiv, Inc. | -105.14 Million USD | 15.845% |
| Guardant Health, Inc. | -479.44 Million USD | 81.545% |
| Biodesix, Inc. | -52.14 Million USD | -69.679% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -3265.521% |
| Precipio, Inc. | -5.85 Million USD | -1411.72% |
| iSpecimen Inc. | -11.09 Million USD | -697.163% |
| Natera, Inc. | -434.8 Million USD | 79.65% |
| Aspira Women's Health Inc. | -16.69 Million USD | -430.144% |
| Standard BioTools Inc. | -74.65 Million USD | -18.518% |
| 23andMe Holding Co. | -666.7 Million USD | 86.729% |
| Castle Biosciences, Inc. | -57.46 Million USD | -53.971% |
| Personalis, Inc. | -108.29 Million USD | 18.297% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -789.519% |
| OpGen, Inc. | -32.66 Million USD | -170.845% |
| T2 Biosystems, Inc. | -50.07 Million USD | -76.69% |
| Myriad Genetics, Inc. | -112 Million USD | 20.999% |
| ICON Public Limited Company | 612.33 Million USD | 114.45% |
| NeoGenomics, Inc. | -87.96 Million USD | -0.583% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -5615.827% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 110.471% |
| RadNet, Inc. | 3.04 Million USD | 3006.735% |
| MDxHealth SA | -43.1 Million USD | -105.292% |
| Psychemedics Corporation | -4.15 Million USD | -2030.019% |
| Illumina, Inc. | -1.16 Billion USD | 92.379% |
| Check-Cap Ltd. | -17.56 Million USD | -403.649% |
| Twist Bioscience Corporation | -208.72 Million USD | 57.609% |
| DarioHealth Corp. | -59.42 Million USD | -48.89% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 47.278% |
| Sera Prognostics, Inc. | -36.24 Million USD | -144.139% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -779.511% |
| OPKO Health, Inc. | -188.86 Million USD | 53.151% |
| Medpace Holdings, Inc. | 282.81 Million USD | 131.286% |
| Neogen Corporation | -9.42 Million USD | -839.189% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -771.154% |
| Prenetics Global Limited | -62.72 Million USD | -41.064% |
| Mainz Biomed B.V. | -26.29 Million USD | -236.484% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -1014.79% |
| Trinity Biotech plc | -24.01 Million USD | -268.395% |
| Neuronetics, Inc. | -30.18 Million USD | -193.09% |
| Sotera Health Company | 51.37 Million USD | 272.222% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -1014.79% |